Abstracts tagged "Fibroblasts"

Abstract Number: 642 • 2017 ACR/ARHP Annual Meeting
Downstream Effects of Apremilast in Human Arthritic Ex Vivo Models
Tue Wenzel Kragstrup^1,2, Søren Lomholt², Morten Aagaard Nielsen², Line Dam Heftdal², Peter H. Schafer³ and Bent Deleuran^2,4, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Translational Development, Celgene Corporation, Summit, NJ, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Apremilast (Otezla) is a PDE4 inhibitor approved for the treatment of psoriasis and psoriatic arthritis, but the mechanisms of action of apremilast are not…
Abstract Number: 1717 • 2017 ACR/ARHP Annual Meeting
Skin Commensal Bacteria Might Affect Wound Repair in SSc By Preventing Fibroblast Activation and By Provoking Chronic Inflammatory Reaction
Masaya Yokota¹, Janine Schniering¹, Oliver Distler² and Britta Maurer³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Chronic digital ulcers (DU) due to peripheral microangiopathy are a major complication in systemic sclerosis (SSc). Chronic wounds are often enriched in bacteria without…
Abstract Number: 763 • 2017 ACR/ARHP Annual Meeting
Mechanisms of Insulin-like Growth Factor-II-Mediated Fibrosis
Sara Garrett¹, Justin Thomas², Eileen Hsu³ and Carol A. Feghali-Bostwick⁴, ¹Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²Eisenhower Medical Center, Rancho Mirage, CA, ³Kaiser Permanente Medical Group, Mclean, VT, ⁴Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: Previous work has shown that insulin-like growth factor (IGF)-II is increased in fibrosing lung diseases, including idiopathic pulmonary fibrosis (IPF) and scleroderma/systemic sclerosis (SSc)-associated…
Abstract Number: 1721 • 2017 ACR/ARHP Annual Meeting
Long Noncoding RNA H19X Is a Key Regulator of Apoptosis and Proliferation of Fibroblasts in Systemic Sclerosis and Other TGFβ-Driven Fibrotic Diseases
Elena Pachera¹, Adam Wunderlin¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj¹, Rucsandra Dobrota¹, Matthias Brock³, Carol A. Feghali-Bostwick⁴, Gerard Dijkstra⁵, Gerhard Rogler⁶, Tobias van Haaften Wouter⁶, Jörg Distler⁷, Gabriela Kania¹ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland, ⁴Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁵Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Switzerland, ⁶Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, ⁷Internal Medicine 3, University of Erlangen, Erlangen, Germany
Background/Purpose: Long noncoding RNAs (lncRNAs) are a class of transcripts regulating gene expression. We have recently identified a novel lncRNA, H19X, which was upregulated in…
Abstract Number: 769 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of Transforming Growth Factor-ß and Points Toward Epidermal Growth Factor Receptor / Phosphatidylinositol 3 Kinase Pathway Inhibition
Benjamin Chaigne¹, Guilhem Clary², Morgane Le Gall³, Nicolas Dumoitier⁴, Sebastien Lofek⁵, Philippe Chafey², Pia Moinzadeh⁶, Thomas Krieg⁷, Christopher Denton⁸ and Luc Mouthon⁹, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, ²INSERM U1016, Institut Cochin,, Paris, France, ³INSERM U1016 Institut Cochin, Paris, France, ⁴INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ⁵INSERM U1016, paris, France, ⁶Department of Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁷Universität zu Köln, Köln, Germany, ⁸Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disorder characterized by autoimmunity, vasculopathy and fibrosis. Fibrosis is due to an exaggerated activation of…
Abstract Number: 1927 • 2017 ACR/ARHP Annual Meeting
Anti-Fibrotic Mechanisms of Endostatin-Derived Peptide Are the Result of Reduction in Pro-Fibrotic Mediators and Promotion of Extracellular Matrix Degradation
Tomoya Watanabe¹, Tetsuya Nishimoto², Takahisa Takihara³, Logan Mlakar⁴, Yunyun Su⁵ and Carol A. Feghali-Bostwick⁶, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Pulmonary Medicine, Tokai University School of Medicine, Isehara, Japan, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, charleston, SC, ⁶Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: Fibrotic disorders such as systemic sclerosis (SSc) result in end-stage organ failure and loss of function, consequently causing high morbidity and mortality. We recently…
Abstract Number: 774 • 2017 ACR/ARHP Annual Meeting
The αV Integrin Inhibitor Abituzumab Inhibits Myofibroblast Differentiation
Eileen Samy¹, Yin Wu¹, Georgianna Higginbotham², Roland Grenningloh² and Daigen Xu², ¹TIP Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Scleroderma is a progressive fibrotic multi-organ disease characterized by the hardening and tightening of the skin and connective tissues. TGF-β1 is a potent mediator…
Abstract Number: 1928 • 2017 ACR/ARHP Annual Meeting
Fibroblast-like Synovial Cell Production of ED-a Fibronectin Contributes to Inflammation in Osteoarthritis
Tue Wenzel Kragstrup^1,2,3, Dong Hyun Sohn⁴, Christin Lepus³, Kazuhiro Onuma⁵, Qian Wang³, William H. Robinson³ and Jeremy Sokolove³, ¹Randers Regional Hospital, Randers, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁴Microbiology and Immunology, Pusan National University School of Medicine, Yangsan, Korea, Republic of (South), ⁵VA Palo Alto Healthcare System and Stanford University, Stanford, CA
Background/Purpose: The pathophysiology of osteoarthritis (OA) involves wear and tear, and a state of low-grade inflammation. Wear and tear leads to tissue degradation followed by…
Abstract Number: 1857 • 2016 ACR/ARHP Annual Meeting
A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis
Christina Wenglén¹, Lars Pettersson², Helena Arozenius² and Gunilla Ekström¹, ¹R&D, AnaMar AB, Lund, Sweden, ²AnaMar AB, Lund, Sweden
Background/Purpose: Methods: Results: Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates…
Abstract Number: 2071 • 2016 ACR/ARHP Annual Meeting
Expression of Neuraminidase 1 (NEU1) Is Upregulated in the Lungs of Scleroderma Patients with Pulmonary Fibrosis, and Gene Delivery of NEU1 to Mouse Lungs Elicits Accumulation of CD8+ Lymphocytes and Collagen
Irina G. Luzina^1,2, Anne E. Wyman^1,2, Virginia Lockatell², Zahid Noor², Nevins W. Todd^1,2, Simeon E. Goldblum^1,2 and Sergei P. Atamas^1,2, ¹Baltimore VA Medical Center, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: We and others have previously reported that pulmonary fibrosis in patients with scleroderma is accompanied by pulmonary accumulation of predominantly CD8+ T lymphocytes. Earlier…
Abstract Number: 2072 • 2016 ACR/ARHP Annual Meeting
Fli1-Haploinsufficient Dermal Fibroblasts Promote Skin-Localized Transdifferentiation of Th2- and Th17-like Regulatory T Cells
Ryosuke Saigusa¹, Yoshihide Asano², Takuya Miyagawa², Megumi Hirabayashi², Kouki Nakamura¹, Shunsuke Miura³, Takashi Yamashita², Yohei Ichimura¹, Takehiro Takahashi¹, Tetsuo Toyama², Takashi Taniguchi¹, Ayumi Yoshizaki², Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁴Arthritis Center, Boston University, Arthritis Center, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem connective tissue disease characterized by autoimmunity/inflammation, vasculopathy, and tissue fibrosis. Fli1 is a member of Ets family transcription…
Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting
Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts
Alvaro Valin¹, Yolanda Ruano², Manuel J. Del Rey³, Carmen M. García-Herrero³, Eduardo Martín-Guerrero¹, Beatriz Bravo⁴, Juan D. Cañete⁵, José L. Rodríguez-Peralto² and Jose L. Pablos^3,6, ¹Grupo de Enfermedades Inflamatorias y Autoimmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ²Pathology Department, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁴Servicio de Traumatología y Cirugía Ortopédica, Hospital 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…
Abstract Number: 2157 • 2016 ACR/ARHP Annual Meeting
Share the Fate: Fibroblast-like Synoviocyte Cell-to-Cell Organelle Transfer Is Directed By the Inflammatory Microenvironment
Ruth Byrne¹, Isabel Olmos Calvo², Thomas Karonitsch³, Felix Kartnig⁴, Johannes Holinka⁵, Günter Steiner⁶, Peter Ertl⁷, Josef Smolen⁸ and Hans Peter Kiener⁹, ¹Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nanotechnology, Austrian Institute for Technology, Vienna, Austria, ³Internal Medicine III, Vienna Medical University, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Orthopaedics, Medical University of Vienna, Vienna, Austria, ⁶Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷Vienna University of Technology, Vienna, Austria, ⁸Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁹Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Fibroblast-like synoviocytes (FLS) form a complex tissue network via long-distance intercellular connections with wide intercellular matrix spaces. The adaptive synovial tissue response to inflammation…
Abstract Number: 806 • 2016 ACR/ARHP Annual Meeting
Single Cell Rnaseq Defines a Unique Transcriptome Profile for Myofibroblasts in the Skin of Patients with Systemic Sclerosis
Robert A. Lafyatis¹, Lisa Rice², Giuseppina Stifano², Jeff Browning^2,3 and Robert W. Simms⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Boston university, Cambridge, MA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Fibrosis in systemic sclerosis (SSc), as well as a wide variety of other fibrotic diseases, is largely driven by myofibroblasts. Myofibroblasts are known to…
Abstract Number: 2556 • 2016 ACR/ARHP Annual Meeting
Deficient Expression of the Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Induces S Phase Arrest in RA Fibroblast-like Synoviocytes (FLS)
Shinji Matsuda¹, Deepa Hammaker², Steven Dowdy³, David L. Boyle⁴ and Gary Firestein⁵, ¹Medicine, UC San Diego, La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³UC San Diego School of Medicine, La Jolla, CA, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Medicine, UCSD, La Jolla, CA
Background/Purpose: LBH (Limb-bud and heart development) was recently identified as an RA risk gene that has abnormally methylated loci and a functional enhancer SNP in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].